白细胞介素-2介导的免疫疗法的阴阳学说 - Suppr

Suppr

超能文献

The yin and yang of interleukin-2-mediated immunotherapy.

作者信息

Bluestone Jeffrey A

出版信息

N Engl J Med. 2011 Dec 1;365(22):2129-31. doi: 10.1056/NEJMe1110900.

DOI:10.1056/NEJMe1110900

PMID:22129258

Abstract

摘要

相似文献

The yin and yang of interleukin-2-mediated immunotherapy.白细胞介素-2介导的免疫疗法的阴阳学说

N Engl J Med. 2011 Dec 1;365(22):2129-31. doi: 10.1056/NEJMe1110900.

A delicate balance: tweaking IL-2 immunotherapy.微妙的平衡：调整白细胞介素-2免疫疗法。

Nat Med. 2012 Feb 6;18(2):208-9. doi: 10.1038/nm0212-208.

Low-dose interleukin-2 and HCV-induced vasculitis.

N Engl J Med. 2012 Apr 5;366(14):1353-4; author reply 1354. doi: 10.1056/NEJMc1200978.

Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis.调节性 T 细胞对 HCV 诱导血管炎的低剂量白细胞介素-2 的反应。

N Engl J Med. 2011 Dec 1;365(22):2067-77. doi: 10.1056/NEJMoa1105143.

Regulatory T cells in graft-versus-host disease.

N Engl J Med. 2012 Mar 8;366(10):962-3; author reply 963. doi: 10.1056/NEJMc1115197.

Regulatory T cells in graft-versus-host disease.

N Engl J Med. 2012 Mar 8;366(10):962; author reply 963. doi: 10.1056/NEJMc1115197.

[Exploring regulatory T cell-based therapy for refractory graft-versus-host disease].

Rinsho Ketsueki. 2014 Jun;55(6):670-81.

Manipulating IL-2 and IL-2R in autoimmune diseases and transplantation.在自身免疫性疾病和移植中调控白细胞介素-2和白细胞介素-2受体

Immunotherapy. 2015;7(12):1231-4. doi: 10.2217/imt.15.94. Epub 2015 Nov 25.

Interleukin-2 and regulatory T cells in graft-versus-host disease.白细胞介素 2 与移植物抗宿主病中的调节性 T 细胞。

N Engl J Med. 2011 Dec 1;365(22):2055-66. doi: 10.1056/NEJMoa1108188.

Therapeutic potential of low-dose IL-2 in a chronic GVHD patient by in vivo expansion of regulatory T cells.低剂量白细胞介素-2通过体内调节性T细胞扩增对慢性移植物抗宿主病患者的治疗潜力。

Cytokine. 2016 Feb;78:22-6. doi: 10.1016/j.cyto.2015.11.020. Epub 2015 Nov 28.

引用本文的文献

A novel dual mechanism-of-action bispecific PD-1-IL-2v armed by a "βγ-only" interleukin-2 variant.一种新型双重作用双特异性 PD-1-IL-2v，由“βγ-仅”白细胞介素-2 变体武装。

Front Immunol. 2024 Apr 4;15:1369376. doi: 10.3389/fimmu.2024.1369376. eCollection 2024.

Low Dose Interleukin-2 Ameliorates Sjögren's Syndrome in a Murine Model.低剂量白细胞介素-2改善小鼠模型中的干燥综合征。

Front Med (Lausanne). 2022 May 19;9:887354. doi: 10.3389/fmed.2022.887354. eCollection 2022.

Increased Serum Interleukin-2 Levels Are Associated with Abnormal Peripheral Blood Natural Killer Cell Levels in Patients with Active Rheumatoid Arthritis.血清白细胞介素-2 水平升高与活动期类风湿关节炎患者外周血自然杀伤细胞水平异常相关。

Mediators Inflamm. 2020 Sep 15;2020:6108342. doi: 10.1155/2020/6108342. eCollection 2020.

Engineering Solutions for Mitigation of Chimeric Antigen Receptor T-Cell Dysfunction.减轻嵌合抗原受体T细胞功能障碍的工程解决方案。

Cancers (Basel). 2020 Aug 18;12(8):2326. doi: 10.3390/cancers12082326.

Prospects of IL-2 in Cancer Immunotherapy.IL-2 在癌症免疫治疗中的前景。

Biomed Res Int. 2018 May 6;2018:9056173. doi: 10.1155/2018/9056173. eCollection 2018.

In vitro differentiated plasmacytoid dendritic cells as a tool to induce anti-leukemia activity of natural killer cells.体外分化的浆细胞样树突状细胞作为诱导自然杀伤细胞抗白血病活性的工具。

Cancer Immunol Immunother. 2017 Oct;66(10):1307-1320. doi: 10.1007/s00262-017-2022-y. Epub 2017 May 29.

CCR8FOXp3 T cells as master drivers of immune regulation.CCR8FOXp3 T 细胞作为免疫调节的主要驱动因素。

Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):6086-6091. doi: 10.1073/pnas.1621280114. Epub 2017 May 22.

Inducing and Administering Tregs to Treat Human Disease.诱导和施用调节性T细胞治疗人类疾病。

Front Immunol. 2016 Jan 22;6:654. doi: 10.3389/fimmu.2015.00654. eCollection 2015.

TRAIL-mediated killing of acute lymphoblastic leukemia by plasmacytoid dendritic cell-activated natural killer cells.浆细胞样树突状细胞激活的自然杀伤细胞通过TRAIL介导杀伤急性淋巴细胞白血病细胞

Oncotarget. 2015 Oct 6;6(30):29440-55. doi: 10.18632/oncotarget.4984.

Tuning IL-2 signaling by ADP-ribosylation of CD25.通过CD25的ADP核糖基化调节白细胞介素-2信号传导。

Sci Rep. 2015 Mar 10;5:8959. doi: 10.1038/srep08959.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验